Obseva announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing. The financing included new investors HBM Healthcare Investments, New Enterprise Associates (NEA), OrbiMed, Rock Springs Capital as well as existing investors Sofinnova Partners, which seeded the company, Sofinnova Ventures, Novo Ventures and MS Ventures.
